{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:47:14Z","timestamp":1792928834544,"version":"4.5.0"},"reference-count":44,"publisher":"Informa UK Limited","issue":"4","funder":[{"name":"funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2021,4,3]]},"DOI":"10.1080\/14712598.2021.1889510","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T20:28:06Z","timestamp":1613334486000},"page":"435-441","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":62,"title":["Brexucabtagene autoleucel for the treatment of relapsed\/refractory mantle cell lymphoma"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6992-4883","authenticated-orcid":false,"given":"Agrima","family":"Mian","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Program, Staff Physician, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland, OH, USA"},{"name":"Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.450"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22367"},{"issue":"1","key":"cit0005","first-page":"18","volume":"91","author":"Nair R","year":"2016","journal-title":"OCL"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-764"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.09.014"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.72"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn045"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00690"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13796"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117956"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15567"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2380"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0067-3"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1227.1227"},{"key":"cit0026","unstructured":"U.S. FDA Approves Kite\u2019s Tecartus\n                      TM\n                      , the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma [Internet]. [cited 2020 Nov 9]. Available from: https:\/\/www.kitepharma.com\/news\/press-releases"},{"key":"cit0027","unstructured":"FDA approved drug products: TECARTUS package insert [Internet]. [cited 2020 Nov 9]. Available from: https:\/\/www.fda.gov\/media\/140409\/download"},{"key":"cit0028","unstructured":"Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refracto.pdf [Internet]. 2020 [cited 2020 Nov 9]. Available from: https:\/\/www.nejm.org\/doi\/suppl\/10.1056\/NEJMoa1914347\/suppl_file\/nejmoa1914347_appendix.pdf"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7006"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"cit0033","unstructured":"Common terminology criteria for adverse events (CTCAE).:80."},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.198812"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16416"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-NB2020-030"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15411"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00438-6"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01013-3"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15643"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-712828"},{"key":"cit0044","unstructured":"Imbruvica prescribing information [Internet]. [cited 2020 Nov 12]. Available from: https:\/\/imbruvica.com\/files\/prescribing-information.pdf"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2021.1889510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T21:51:53Z","timestamp":1618609913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2021.1889510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,3]]}},"alternative-id":["10.1080\/14712598.2021.1889510"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2021.1889510","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}